Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus granulosus | dihydrofolate reductase | 0.2818 | 1 | 1 |
Echinococcus granulosus | solute carrier family 2 facilitated glucose | 0.0125 | 0.0065 | 0.0065 |
Mycobacterium tuberculosis | Dihydrofolate reductase DfrA (DHFR) (tetrahydrofolate dehydrogenase) | 0.2818 | 1 | 1 |
Schistosoma mansoni | dihydrofolate reductase | 0.2818 | 1 | 1 |
Onchocerca volvulus | 0.0791 | 0.2523 | 0.5 | |
Schistosoma mansoni | bifunctional dihydrofolate reductase-thymidylate synthase | 0.0791 | 0.2523 | 0.2475 |
Echinococcus multilocularis | solute carrier family 2 facilitated glucose | 0.0125 | 0.0065 | 0.0065 |
Loa Loa (eye worm) | thymidylate synthase | 0.0791 | 0.2523 | 0.2475 |
Trypanosoma cruzi | dihydrofolate reductase-thymidylate synthase | 0.2115 | 0.7406 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0126 | 0.0069 | 0.0004 |
Echinococcus granulosus | solute carrier family 2 facilitated glucose | 0.0125 | 0.0065 | 0.0065 |
Echinococcus multilocularis | thymidylate synthase | 0.0791 | 0.2523 | 0.2523 |
Mycobacterium ulcerans | dihydrofolate reductase DfrA | 0.2818 | 1 | 1 |
Echinococcus granulosus | solute carrier family 2 facilitated glucose | 0.0125 | 0.0065 | 0.0065 |
Echinococcus granulosus | solute carrier family 2 facilitated glucose | 0.0125 | 0.0065 | 0.0065 |
Leishmania major | dihydrofolate reductase-thymidylate synthase | 0.2115 | 0.7406 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0469 | 0.1334 | 0.1277 |
Echinococcus granulosus | thymidylate synthase | 0.0791 | 0.2523 | 0.2523 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0376 | 0.0993 | 1 |
Mycobacterium tuberculosis | Probable thymidylate synthase ThyA (ts) (TSASE) | 0.0791 | 0.2523 | 0.1699 |
Echinococcus multilocularis | solute carrier family 2 facilitated glucose | 0.0125 | 0.0065 | 0.0065 |
Echinococcus multilocularis | solute carrier family 2 facilitated glucose | 0.0125 | 0.0065 | 0.0065 |
Echinococcus multilocularis | dihydrofolate reductase | 0.2818 | 1 | 1 |
Toxoplasma gondii | bifunctional dihydrofolate reductase-thymidylate synthase | 0.2115 | 0.7406 | 1 |
Plasmodium vivax | bifunctional dihydrofolate reductase-thymidylate synthase, putative | 0.2115 | 0.7406 | 1 |
Chlamydia trachomatis | dihydrofolate reductase | 0.2818 | 1 | 0.5 |
Echinococcus multilocularis | solute carrier family 2, facilitated glucose | 0.0125 | 0.0065 | 0.0065 |
Mycobacterium leprae | DIHYDROFOLATE REDUCTASE DFRA (DHFR) (TETRAHYDROFOLATE DEHYDROGENASE) | 0.2818 | 1 | 1 |
Plasmodium falciparum | bifunctional dihydrofolate reductase-thymidylate synthase | 0.2115 | 0.7406 | 1 |
Loa Loa (eye worm) | dihydrofolate reductase | 0.2818 | 1 | 1 |
Brugia malayi | hypothetical protein | 0.0376 | 0.0993 | 0.0935 |
Brugia malayi | Amyloid A4 extracellular domain containing protein | 0.0595 | 0.1799 | 0.1745 |
Schistosoma mansoni | alzheimer's disease beta-amyloid related | 0.0217 | 0.0405 | 0.0343 |
Trypanosoma brucei | dihydrofolate reductase-thymidylate synthase | 0.2115 | 0.7406 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0252 | 0.0534 | 0.0472 |
Brugia malayi | thymidylate synthase | 0.0791 | 0.2523 | 0.2475 |
Brugia malayi | Dihydrofolate reductase | 0.2818 | 1 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
ED2 (functional) | 0 mg kg-1 | Dose necessary for bringing about a doubled shift of the dose pressor reaction curve to the right in anesthetized wistar kyoto male rats; NT means not tested | ChEMBL. | No reference |
pA2 (functional) | = 6.4 | Potency of the Angiotensin II-induced contraction of rabbit aortic strips | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.